In order to reduce the risk of infusion-related reactions, participants enrolled in all study parts are recommended to receive premedication 30 minutes prior to initiation of study treatment. Recommended premedications include a H1 histamine anta gonist, such as diphenhydramine 50 mg (or equivalent), and an anti pyretic, such as acetaminophen/par acetamol 325 to 1000 mg (or equivalent). Premedication should be administere d prior to infusion of any study drug, and should comply with the pe rmitted med ications and dosi ng described in Section 7.6 .